29 results
8-K
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
Review and Compensation Committees. Mr. Rosiello led the work that shifted McKinsey’s recruiting toward non-MBAs and developed innovative leadership … 2011, advancing the company’s portfolio of new, innovative prodrugs from discovery to clinical proof-of-concept. Earlier, Mr. Straight Nissen served
8-K
EX-99.1
AXLA
Axcella Health Inc.
3 Mar 21
Axcella Announces Alison D. Schecter, M.D., as President of R&D
5:26pm
for our innovative, efficient and highly informative development model. Her impressive experience across the drug development lifecycle will be valuable
PRE 14A
AXLA
Axcella Health Inc.
7 Aug 23
Preliminary proxy
4:15pm
: ASND) from April 2008 to June 2011, advancing the company’s portfolio of new, innovative prodrugs from discovery to clinical proof-of-concept … of Cardiovascular, Renal and Metabolic Diseases Innovative Medicines and Early Development. Dr. Rondinone served in different roles in research and development
DEF 14A
f6fl1
3 Apr 20
Definitive proxy
4:15pm
424B4
wd427uh3p8ipj r5a9y
9 May 19
Prospectus supplement with pricing info
4:29pm
DRS/A
49x0d8wbljrhz
15 Mar 19
Draft registration statement (amended)
12:00am
S-1/A
96iwa
30 Apr 19
IPO registration (amended)
6:06am
DRS
x2n4j73 4f1
28 Jan 19
Draft registration statement
12:00am
S-1
immmwc6 o2b
12 Apr 19
IPO registration
7:02am